Showing results (591-600 of 1,892) with videos related to
Sort By:
Pageof 190
Immunotherapy|October 19, 2021
Unconventional radiotherapy to enhance immunotherapy efficacy in bulky tumors: a case reportMariangela Massaccesi, Luca Boldrini, Angela Romano, et al.Immunotherapy|October 13, 2021
Bispecific antibodies in colorectal cancer therapy: recent insights and emerging conceptsFarideh Ghalamfarsa, Seyyed Hossein Khatami, Omid Vakili, et al.Immunotherapy|October 14, 2021
Use of upadacitinib in the treatment of psoriatic arthritisYael Ross, Marina MagreyImmunotherapy|October 28, 2021
Association between PD-L1 inhibitor, tumor site and adverse events of potential immune etiology within the US FDA adverse event reporting systemOmar Abdel-RahmanImmunotherapy|July 13, 2022
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factorsMaja Guberina, Nika Guberina, Christoph Pöttgen, et al.Immunotherapy|July 13, 2022
Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysisYan Wang, Haiyun HeImmunotherapy|July 19, 2022
Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case reportGuixian Wu, Jing Huang, Ling Lin, et al.Immunotherapy|July 20, 2022
Mesenchymal stem cell treatment for hyperactive immune response in patients with COVID-19Ragul Manoharan, Rajshekhar A Kore, Jawahar L MehtaImmunotherapy|April 21, 2022
Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry studyMichael Borte, Stefan Raffac, Martin Hrubiško, et al.Immunotherapy|June 13, 2019
The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?Elie Rassy, Ziad Bakouny, Tarek Assi, et al.Pageof 190